In an unusual move, a pair of academics is escalating an effort to convince Gilead Sciences (GILD) to test a compound that is not only known for saving cats from a fatal virus, but is highly similar to remdesivir and, therefore, may be useful in combating Covid-19.
At issue is a Gilead compound known as GS-441524, which works in the same way as remdesivir to inhibit viruses, according to research conducted partly by the company (more here). The compound has not been tested in humans, but has been sold on black markets to repel feline infectious peritonitis, which is caused by a different coronavirus than the virus that causes Covid-19.
In May, researchers at the University of Texas MD Anderson Cancer Center argued publicly that Gilead should study the compound to fight Covid-19. But their effort failed to sway the drug maker and subsequent talks have gone nowhere. Now, they have teamed with Public Citizen to urge Gilead to run tests. Their letter was also sent to the National Institute of Health and the Food and Drug Administration in hopes of pressuring the company.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect